GSK’s Linerixibat Demonstrates Efficacy in Phase III GLISTEN Study for Cholestatic Pruritus
UK-based pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK) has announced positive headline results from the Phase...
Clinical trial results
MSD Announces Positive Topline Results from Phase III Subcutaneous Keytruda Trial
US-based Merck, Sharp & Dohme Inc., (MSD, NYSE: MRK) has released positive topline results from...
Brii Biosciences’ Elebsiran Shows Promising Results in Phase II ENSURE Study for Chronic HBV
China-based Brii Biosciences Ltd (HKG: 2137) has published the latest data from its ongoing Phase...
UCB and Biogen’s Dapirolizumab Pegol Shows Promise in Phase III SLE Study
Partners UCB (FRA: UNC) and Biogen Inc. (NASDAQ: BIIB) have announced positive results from a...
Rona Therapeutics’ RN0191 Showcases Positive Phase I Results at AHA Scientific Sessions
Shanghai-based nucleic acid drug developer Rona Therapeutics has announced the presentation of positive Phase I...
Eli Lilly’s Tirzepatide Meets Primary Endpoints in Phase III SUMMIT Heart Failure Study
Eli Lilly and Company (NYSE: LLY), a leading US pharmaceutical corporation, has announced positive results...
Eli Lilly’s Muvalaplin Demonstrates Potent Lp(a) Reduction in Phase II Study
Eli Lilly & Co. (NYSE: LLY), a leading US pharmaceutical company, has announced positive results...
TenNor Therapeutics’ Rifasutenizol Shows High Eradication Rate in H. pylori Phase III Study
China-based TenNor Therapeutics has announced positive results from its Phase III clinical study for rifasutenizol...
GSK’s Blenrep Shows Survival Benefit in Phase III Multiple Myeloma Study
UK-based pharmaceutical company GSK plc (NYSE: GSK) has reported positive results from a Phase III...
Janssen-Cilag’s Nipocalimab Shows Promise in Phase II Study for Sjögren’s Disease
Janssen-Cilag International NV, a subsidiary of Johnson & Johnson (J&J, NYSE: JNJ), has unveiled the...
Eli Lilly’s Tirzepatide Shows Sustained Weight Loss in 176-Week Study
US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has released 176-week follow-up data from...
Gan & Lee’s GZR18 Shows Significant Weight Loss in Phase IIb Study at ObesityWeek 2024
Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced the oral presentation...
BeyondSpring Presents Positive Phase II Data for Plinabulin Combination Therapy in NSCLC at SITC
BeyondSpring Inc. (NASDAQ: BYSI), a US-based biotech company, has announced the presentation of the latest...
Abbisko Therapeutics’ Pimicotinib Meets Primary Endpoint in Phase III MANEUVER Study for TGCT
hanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has revealed positive top-line results from the...
AstraZeneca’s Tezspire Meets Phase III Co-Primary Endpoints in CRSwNP Study
AstraZeneca Inc., (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has announced positive high-level results...
Alphamab Oncology Presents JSKN033 Phase I/II Study Results at SITC 2024
Alphamab Oncology (HKG: 9966), a China-based biopharmaceutical company, has announced the presentation of the latest...
Ascletis Pharma’s ASC47 Showcases Promising Weight Loss Results in Phase I Clinical Trial
Ascletis Pharma Inc. (HKG: 1672), a China-based pharmaceutical company, has announced positive results from a...
HutchMed to Present Updated Data from Solvleplenib ESLIM-01 Phase III Trial at ASH and ESMO Congress 2024
China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced plans to present new and...
CARSgen Therapeutics Presents Latest CAR-T Data at ASH Annual Meeting
CARSgen Therapeutics Holdings Ltd (HKG: 2171), a China-based specialist in chimeric antigen receptor (CAR)-T cell...
Ascentage Pharma to Present Olverembatinib and Lisaftoclax Clinical Data at ASH Annual Meeting
China-based Ascentage Pharma (HKG: 6855) has announced that it will present the results of multiple...